Synaptic density,
delivered.
A direct, scalable ¹⁸F SV2A PET tracer. SV2A sits on essentially every synaptic vesicle in the brain — a quantitative readout of the physical substrate of cognition, measurable while patients are still cognitively normal.
CONTROL · 74 y
MCI · 73 y
ALZHEIMER'S · 82 ySynapse density itself
SV2A sits on essentially every synaptic vesicle in the brain, making the signal a quantitative measure of the physical substrate of cognition.
Detectable while cognition is still normal
Synaptic loss is the earliest functional change in neurodegeneration — years before symptoms — and it tracks cognition closely.
Ships hub-and-spoke to any PET center
The 110-minute ¹⁸F half-life allows central production and distribution on existing radiopharmacy networks. No on-site cyclotron needed.
57 million people live with dementia today. Most are diagnosed late, if at all.
The number is heading toward 139 million by 2050, at a global care cost of $1.3 trillion a year (WHO). Roughly 75% of cases go undiagnosed (ADI 2021). Measuring synaptic density directly — early, quantitatively, and at any PET center — changes when and how the disease can be seen.
Covering both molecules.
[¹⁸F]SynVesT-1 is the tracer at the center of the FNIH's SV2A PET Project: the Biomarkers Consortium program cementing SV2A PET's status as a biomarker of synaptic density.
Safety, biodistribution and dosimetry in the literature; test–retest under 9%.